MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.310
+0.060
+2.67%
After Hours: 2.310 0 0.00% 19:09 09/24 EDT
OPEN
2.250
PREV CLOSE
2.250
HIGH
2.320
LOW
2.220
VOLUME
316.78K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
1.780
MARKET CAP
171.20M
P/E (TTM)
-2.0673
1D
5D
1M
3M
1Y
5Y
BRIEF-Calithera Biosciences Says On September 14, 2021, Co Entered Into A Settlement Agreement And Release With Incyte
reuters.com · 09/16 20:11
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it will present a tria...
GlobeNewswire · 09/08 11:00
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cance...
GlobeNewswire · 09/02 11:00
Shareholders in Calithera Biosciences (NASDAQ:CALA) are in the red if they invested three years ago
Calithera Biosciences, Inc. ( NASDAQ:CALA ) shareholders should be happy to see the share price up 19% in the last...
Simply Wall St. · 08/26 10:32
BRIEF-Calithera Biosciences Q2 Revenue $3.0 Million
reuters.com · 08/05 22:06
Calithera Biosciences EPS beats by $0.05
Calithera Biosciences (NASDAQ:CALA): Q2 GAAP EPS of -$0.19 beats by $0.05. Revenue of $3M. Cash, cash equivalents and investments totaled $92.2M as of June 30, 2021. Press Release
Seekingalpha · 08/05 20:51
Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021-- SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. ...
GlobeNewswire · 08/05 20:05
Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the ...
GlobeNewswire · 07/29 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CALA. Analyze the recent business situations of Calithera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CALA stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 135
Institutional Holdings: 55.95M
% Owned: 75.50%
Shares Outstanding: 74.11M
TypeInstitutionsShares
Increased
22
4.42M
New
15
1.73M
Decreased
29
8.09M
Sold Out
37
3.34M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Susan Molineaux
Chief Financial Officer/Secretary/IR Contact Officer
Stephanie Wong
Senior Vice President/Chief Compliance Officer/General Counsel
Sumita Ray
Senior Vice President
Christopher Molineaux
Senior Vice President
Francesco Parlati
Senior Vice President
Eric Sjogren
Other
Keith Orford
Lead Director/Independent Director
Deepa Pakianathan
Independent Director
Sunil Agarwal
Independent Director
Jonathan Drachman
Independent Director
Scott Garland
Independent Director
Jean George
Independent Director
Suzy Jones
Independent Director
Blake Wise
Independent Director
H. Ward Wolff
No Data
About CALA
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.